Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.
biomarkers
hepatocellular carcinoma
immunotherapy
tumor mutation burden
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
18 Jun 2019
18 Jun 2019
Historique:
received:
16
01
2019
accepted:
20
05
2019
entrez:
2
7
2019
pubmed:
2
7
2019
medline:
2
7
2019
Statut:
epublish
Résumé
The clinical deployment of immune checkpoint inhibitors (ICIs) has created a tandem drive for the identification of biomarkers linked to benefit. Comprehensive genomic profiling was performed to evaluate the frequency of genomic biomarkers of ICI response in 755 patients with advanced hepatocellular carcinoma (HCC). Median age was 62 years' old, 73% were male, 46% had extrahepatic disease, 107 had documented hepatitis C, 96 had hepatitis B and 4 patients were coinfected. Median tumor mutation burden (TMB) was 4 mutations/Mb and only 6 tumors (0.8%) were TMB-high. Out of 542 cases assessed for microsatellite instability (MSI), one (0.2%) was MSI-high and TMB-high. Twenty-seven (4%) patients had
Identifiants
pubmed: 31258846
doi: 10.18632/oncotarget.26998
pii: 26998
pmc: PMC6592287
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4018-4025Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST SMA, JSR, EAS, DF, JS, RM and SZM are employees of Foundation Medicine.
Références
Histopathology. 2012 May;60(6):943-52
pubmed: 22348534
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nat Genet. 2013 Feb;45(2):136-44
pubmed: 23263490
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Oncotarget. 2015 Oct 27;6(33):34221-7
pubmed: 26439694
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700
pubmed: 26484443
J Surg Oncol. 2016 Jan;113(1):55-61
pubmed: 26661118
Nat Rev Cancer. 2016 Feb;16(2):71-81
pubmed: 26822575
Curr Oncol Rep. 2016 Apr;18(4):21
pubmed: 26922327
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
J Hepatol. 2016 Nov;65(5):1031-1042
pubmed: 27262756
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7
pubmed: 27333219
J Natl Compr Canc Netw. 2017 Feb;15(2):142-147
pubmed: 28188185
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Eur J Cancer. 2017 Oct;84:290-303
pubmed: 28846956
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):329-339
pubmed: 28871000
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
J Clin Oncol. 2018 Jun 10;36(17):1685-1694
pubmed: 29489427
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155